Altimmune (ALT) Jumps 23% on Consensus Recommendation of “Buy” Rating
Altimmune, Inc. (ALT) jumped 23% today after receiving a consensus recommendation of “Buy” from brokerage analysts. Out of seven analysts that are covering ALT, five rated the stock with a buy rating, with an average 12-month price target of $25.00.
At the current stock price of around $9.00, analysts are seeing a lot of room to grow.
ALT is housed in the PRISM Vaccines & Cell Therapy Index, which is up 4.2% for the day. ALT was the strongest performer for the day, with ATHX suffering the biggest loss, being down 13.5% for the day.
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.